Delta Asset Management LLC TN decreased its position in Becton Dickinson and Co (NYSE:BDX) by 0.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 88,187 shares of the medical instruments supplier’s stock after selling 648 shares during the period. Becton Dickinson and accounts for about 2.7% of Delta Asset Management LLC TN’s investment portfolio, making the stock its 15th biggest holding. Delta Asset Management LLC TN’s holdings in Becton Dickinson and were worth $18,878,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Family Firm Inc. boosted its stake in shares of Becton Dickinson and by 0.5% during the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock valued at $236,000 after buying an additional 6 shares during the period. Northwest Quadrant Wealth Management LLC boosted its stake in shares of Becton Dickinson and by 0.4% during the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock valued at $332,000 after buying an additional 6 shares during the period. NBT Bank N A NY boosted its stake in shares of Becton Dickinson and by 0.3% during the 2nd quarter. NBT Bank N A NY now owns 3,351 shares of the medical instruments supplier’s stock valued at $654,000 after buying an additional 10 shares during the period. Good Life Advisors LLC boosted its stake in shares of Becton Dickinson and by 0.6% during the 2nd quarter. Good Life Advisors LLC now owns 2,494 shares of the medical instruments supplier’s stock valued at $491,000 after buying an additional 14 shares during the period. Finally, Pathstone Family Office LLC boosted its stake in shares of Becton Dickinson and by 0.4% during the 2nd quarter. Pathstone Family Office LLC now owns 3,974 shares of the medical instruments supplier’s stock valued at $2,530,000 after buying an additional 15 shares during the period. 75.57% of the stock is owned by hedge funds and other institutional investors.

BDX has been the subject of several analyst reports. Bank of America reaffirmed a “buy” rating and issued a $260.00 price objective on shares of Becton Dickinson and in a research note on Friday. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price objective for the company in a research note on Friday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 price objective on shares of Becton Dickinson and in a research note on Friday, November 3rd. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $230.00 price objective (up previously from $210.00) on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Morgan Stanley lifted their price objective on shares of Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $233.80.

Shares of Becton Dickinson and Co (BDX) traded up $2.20 on Tuesday, reaching $236.71. 1,324,300 shares of the company traded hands, compared to its average volume of 1,594,943. The company has a market cap of $53,900.00, a P/E ratio of 50.91, a PEG ratio of 1.79 and a beta of 1.07. Becton Dickinson and Co has a 12-month low of $169.19 and a 12-month high of $236.74. The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping the consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The business’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.12 EPS. equities research analysts forecast that Becton Dickinson and Co will post 10.66 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be issued a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.27%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 64.52%.

TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/01/23/becton-dickinson-and-co-bdx-position-reduced-by-delta-asset-management-llc-tn.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.